Income Statement Cytokinetics, Incorporated
Stocks
CYTK
US23282W6057
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.45 USD | -1.46% |
|
-4.37% | +6.42% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 70.43M | 7.59M | 7.53M | 18.47M | 88.04M | |||||
Other Revenues, Total | - | 87M | - | - | - | |||||
Total Revenues | 70.43M | 94.59M | 7.53M | 18.47M | 88.04M | |||||
Cost of Goods Sold, Total | 160M | 241M | 330M | 339M | 416M | |||||
Gross Profit | -89.51M | -146M | -323M | -321M | -328M | |||||
Selling General & Admin Expenses, Total | 96.8M | 178M | 174M | 215M | 284M | |||||
Other Operating Expenses, Total | 96.8M | 178M | 174M | 215M | 284M | |||||
Operating Income | -186M | -324M | -496M | -536M | -612M | |||||
Interest Expense, Total | -29.33M | -51.16M | -57.67M | -86.51M | -104M | |||||
Interest And Investment Income | 331K | 11.34M | 27.63M | 51.53M | 48.42M | |||||
Net Interest Expenses | -29M | -39.81M | -30.04M | -34.98M | -55.45M | |||||
Other Non Operating Income (Expenses) | - | - | - | -18.3M | 4M | |||||
EBT, Excl. Unusual Items | -215M | -364M | -526M | -590M | -664M | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | - | -24.94M | - | - | -121M | |||||
EBT, Incl. Unusual Items | -215M | -389M | -526M | -590M | -785M | |||||
Earnings From Continuing Operations | -215M | -389M | -526M | -590M | -785M | |||||
Net Income to Company | -215M | -389M | -526M | -590M | -785M | |||||
Net Income - (IS) | -215M | -389M | -526M | -590M | -785M | |||||
Net Income to Common Incl Extra Items | -215M | -389M | -526M | -590M | -785M | |||||
Net Income to Common Excl. Extra Items | -215M | -389M | -526M | -590M | -785M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -2.8 | -4.33 | -5.45 | -5.26 | -6.54 | |||||
Basic EPS - Continuing Operations | -2.8 | -4.33 | -5.45 | -5.26 | -6.54 | |||||
Basic Weighted Average Shares Outstanding | 76.89M | 89.82M | 96.52M | 112M | 120M | |||||
Net EPS - Diluted | -2.8 | -4.33 | -5.45 | -5.26 | -6.54 | |||||
Diluted EPS - Continuing Operations | -2.8 | -4.33 | -5.45 | -5.26 | -6.54 | |||||
Diluted Weighted Average Shares Outstanding | 76.89M | 89.82M | 96.52M | 112M | 120M | |||||
Normalized Basic EPS | -1.75 | -2.53 | -3.41 | -3.29 | -3.45 | |||||
Normalized Diluted EPS | -1.75 | -2.53 | -3.41 | -3.29 | -3.45 | |||||
Supplemental Items | ||||||||||
EBITDA | -184M | -318M | -484M | -527M | -602M | |||||
EBITA | -186M | -324M | -496M | -536M | -612M | |||||
EBIT | -186M | -324M | -496M | -536M | -612M | |||||
EBITDAR | - | - | - | - | - | |||||
Total Revenues (As Reported) | 70.43M | 94.59M | 7.53M | 18.47M | 88.04M | |||||
Normalized Net Income | -135M | -228M | -329M | -368M | -415M | |||||
Interest on Long-Term Debt | 16.3M | 19.1M | 28.1M | 32.8M | 45.5M | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 96.8M | 178M | 174M | 215M | 284M | |||||
Research And Development Expense From Footnotes | 160M | 241M | 330M | 339M | 416M | |||||
Net Rental Expense, Total | - | - | - | - | - | |||||
Imputed Operating Lease Interest Expense | - | - | - | - | - | |||||
Imputed Operating Lease Depreciation | - | - | - | - | - | |||||
Stock-Based Comp., COGS (Total) | 10.46M | 19.1M | 32.13M | 44.01M | 54.54M | |||||
Stock-Based Comp., G&A Exp. (Total) | 16.37M | 28.75M | 39.93M | 53.83M | 57.75M | |||||
Total Stock-Based Compensation | 26.83M | 47.85M | 72.06M | 97.84M | 112M |
- Stock Market
- Stocks
- CYTK Stock
- Financials Cytokinetics, Incorporated
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















